

OCCASIONAL NOTES

Yeast, Flies, Worms, and Fish in the Study of Human Disease

Iswar K. Hariharan, M.B., B.S., Ph.D., and Daniel A. Haber, M.D., Ph.D.

The sequencing of the human genome has revealed an almost complete “parts list” for the study of the genetic basis of disease.^{1,2} The Online Mendelian Inheritance in Man data base lists more than 1000 human genes that have been implicated in specific diseases.³ It is likely that within a few years the causative lesion in most diseases that result from a mutation in a single gene will have been characterized, and geneticists are using sophisticated methods to track genes in polygenic diseases — that is, diseases caused by defects in more than a single gene.

Often, however, the rapid pace of the discovery of disease-causing genes is not matched by the pace of our understanding of how these genes cause the clinical manifestations of a disease. In the search for the genetic basis of a disease, it is not uncommon to discover an abnormal protein the normal function of which is not known. Some information about a novel protein may be gained by studying its distribution in normal tissues and their subcellular compartments and by examining the consequences of overexpression of the protein in cultured cells or inactivation of the corresponding gene in knockout mice. These investigative approaches are an important starting point, but they may not help in understanding the role of a novel gene in the functional context of known signaling pathways. They also are not easily adaptable to high-throughput analyses, in which tens of thousands of mutant organisms can be screened for alterations in specific biochemical pathways, or to testing large libraries of chemicals for their effects on abnormal phenotypes. Analyses with relatively simple organisms, however, which at first seem remote from humans, are likely to help reveal the function of genes implicated in human disease. These simple organisms include the yeast *Saccharomyces cerevisiae*, the fruitfly *Drosophila melanogaster*, the nematode *Caenorhabditis elegans* (hereafter referred to as yeast, fly, and worm, respectively), and the zebrafish *Danio rerio*.

YEAST, FLIES, WORMS, AND FISH

The use of simple model organisms in biologic research is certainly not new. Indeed, much of the knowledge of the fundamentals of gene regulation comes from studies that were conducted in bacteria,⁴ reportedly leading Jacques Monod to remark, “What is true for [*Escherichia coli*] is also true for the elephant.” Two premises underlie the use of simple organisms in medical research. First, most of the important biologic processes have remained essentially unchanged throughout evolution — that is, they are conserved in humans and simpler organisms. Second, these processes are easier to unravel in simple organisms than in humans. The short generation times of yeast, flies, worms, and zebrafish accelerate genetic studies in these organisms. Mutant strains can be generated efficiently, and the mutations responsible for specific phenotypes can be identified rapidly. Moreover, the effects of gene inactivation or overexpression, as well as interactions among different genes, can readily be identified. Like the human genome, the genomes of the yeast, fly, and worm have been almost fully sequenced,⁵⁻⁷ and completion of the zebrafish genome is expected within a few years. The ability to compare evolutionarily conserved gene-family members (orthologues) among these species is one of the important benefits of the genome projects.

The genetic approaches used to study each of these organisms have been reviewed recently elsewhere.⁸⁻¹¹ In this article, we provide an overview of their usefulness in studying genes with direct relevance to human disease. Although some laboratories are now conducting large-scale mutagenesis screening in mice, the discussion here is restricted to nonmammalian organisms.

IDENTIFYING GENES CAUSING HUMAN DISEASE IN MODEL ORGANISMS


It is thought that 60 to 80 percent of disease-causing genes in humans have orthologues in the fly genome.^{12,13} This estimate depends on the stringency of the criteria used to identify similarities in amino acid sequences, and the proportion may be even higher when functional studies are used to uncover related genes. Worms appear to have slightly fewer orthologues of human genes than do flies.¹² The vertebrate zebrafish is likely to have a counterpart for almost every disease-causing gene in humans. For this reason, these small, nearly transparent fish have been subjected to large-scale mutagenesis experiments, which produce numerous mutants with a wide variety of defects in organ development that can be readily detected under low magnification¹⁴ (Fig. 1). Completion of the sequencing of the ze-


brafish genome will greatly facilitate the isolation of genes responsible for abnormalities in vertebrate organ development. In addition, the consequences of the abnormal expression of genes can be studied at the level of the whole organism in zebrafish. For example, the generation of *c-myc*-driven T-cell leukemia cells can be monitored in real time by means of a green fluorescent protein marker as they are disseminated from the thymus to other organs.¹⁵

Beyond the conservation of gene sequences across species, the usefulness of a model organism is dictated primarily by its suitability for the study of particular cellular pathways. For instance, the understanding of genes involved in regulating the cell cycle and of the checkpoints that monitor for damaged DNA began with studies in yeast cells, which are particularly well suited for investigations of the effects of mutations on cell division¹⁶⁻¹⁸ (Fig. 2). Similarly, much of the understanding of genes that regulate the organization of tissues and the differentiation of cells in the human embryo is based on insights gained from studies of mutations that perturb segmentation in the fly embryo.¹⁹ Genetic studies in the worm, in which it is feasible to account for the developmental fate of each of the animal's 1090 cells, improved the understanding of apoptosis (programmed cell death).²⁰ Research in flies, yeast, and worms led to Nobel prizes in 1995, 2001, and 2002, respectively.

DISCOVERING NEW GENES

Studies in model organisms often reveal the first clues to the identity of a genetic defect in a human disease. For instance, the instability of mononucleotide and dinucleotide repeat sequences (microsatellite DNA) in colorectal cancer cells from patients with hereditary nonpolyposis colon cancer (the Lynch syndrome) resembles the defects in DNA replication seen in yeast cells with defective mismatch repair genes. Indeed, inactivating mutations of the human orthologues of these yeast genes, the *MSH2* and *MLH1* genes, are the most frequent causes of familial colon cancer.²¹ Similarly, gene-mapping studies of families affected by the basal-cell nevus syndrome (Gorlin's syndrome) narrowed the search to a chromosomal locus that carries the orthologue of the fly gene *patched*. In flies, mutations in this gene alter the differentiation of groups of cells in the embryonic epidermis. Remarkably, germ-line mutations in the human orthologue of *patched* occur in Gorlin's syndrome, and somatic mutations in





patched are evident in most cases of sporadic basal-cell carcinoma of the skin.^{22,23}

Genetic screening in flies, worms, or yeast can also help to identify genes that regulate cell proliferation. Both the yeast *CDC4* gene and its fly orthologue *archipelago* (*ago*) are involved in a mechanism that suppresses cell proliferation by promoting the degradation of cyclin E, a protein required for entry into S phase—the phase of DNA synthesis—of the cell cycle.^{24–26} The human orthologue *hCDC4/hAGO* has a similar function and is mutated in breast and

ovarian cancer cell lines^{24,25} and in up to 16 percent of endometrial carcinomas.²⁷ Another example is the protein ferroportin1, which in humans is hypothesized to export cellular iron into the circulation and which was first identified in anemic zebrafish.²⁸ The human orthologue of the *ferroportin1* gene was subsequently shown to be mutated in certain cases of hemochromatosis.^{29,30} As these examples suggest, the relative ease with which newly identified genes can be linked to phenotypes in model organisms makes the use of such organisms

a powerful approach for identifying their orthologues involved in human diseases.

DEFINING CELLULAR PATHWAYS

Model organisms provide researchers with a unique method of placing genes within a functional pathway — the so-called modifier screen.^{9,10} This method involves inducing random mutations in an organism known to have a specific mutation in a gene of interest. The added mutations in other genes may modify the usual phenotype, thereby providing clues to the molecular pathway in which the gene of interest is important. Modifier genes, as those identified with this method are called, often function in the same cellular pathway as the gene of interest. For example, overexpression of a gene in the highly organized compound eye of the fly causes a defect that is easily measured. This defect may be exacerbated or suppressed by a mutation in another gene that functions in the same pathway. Inducing random mutations in the fly genome with the use of a chemical mutagen or irradiation allows tens of thousands of flies to be screened for the rare individual in which a mutation alters the phenotype of the initial mutant strain (Fig. 3).

Modifier screening has been used to gain insight into disease-causing genes implicated in human neurodegeneration.³¹ Abnormal expansion of the stretches of glutamines in specific proteins underlies Huntington's disease, spinocerebellar atrophy, and other inherited neurologic diseases.³² Remarkably, the expression of proteins engineered to contain polyglutamine stretches in flies or worms also triggers neurodegeneration, and, as in human neurodegeneration, the severity correlates with the length of the polyglutamine stretch.³³⁻³⁵ Modifier screening in flies has shown that reduced activity of cellular heat-shock proteins, which facilitate the correct folding of proteins, hastens neurodegeneration, whereas overexpression of heat-shock proteins has a protective effect.³⁶⁻³⁸ Similar experiments have also suggested that polyglutamine stretches interfere with histone acetyltransferases, which regulate gene expression by adding acetyl groups to the histones that encase chromatin. Drugs known to inhibit the opposing histone deacetylases, and hence to restore histone acetylation, slow neurodegeneration in the fly model,³⁹ an observation with implications for neurodegeneration in humans.

Similar genetic screening may prove to be of interest in the study of Parkinson's disease. In the fly,

overexpression of the gene for α -synuclein, which has been implicated in the human disease, causes degenerative changes in dopaminergic neurons and abnormalities in movement.⁴⁰ A model of early-onset Alzheimer's disease has been established in the worm by mutation of its orthologue of the human gene *PRESENILIN*. The effects of the mutation are reversed by overexpression in the worm of the human transmembrane proteins APH-1 and PEN-2.⁴¹ Further study of these proteins may yield insights into the function of presenilins and may thus suggest new therapeutic targets.

The discovery of RNA-mediated interference (RNAi), a scientific breakthrough first achieved in the worm and recently extended to the fly and mammalian cells, is likely to revolutionize the study of gene function.⁴² The introduction into cells of double-stranded RNA molecules complementary to a particular gene triggers degradation of the endogenous messenger RNA through a specific nuclease pathway. RNAi provides the basis for a strategy for rapidly inactivating any gene of interest. In the worm, RNAi is so potent that when the adult organism is fed bacteria engineered to contain the appropriate double-stranded RNA, the endogenous messenger RNA will degrade in virtually all cells (Fig. 4). Worms with a mutant phenotype can be grown in thousands of wells, each containing bacteria expressing a different double-stranded RNA. The RNA that enhances or suppresses the mutant phenotype is thus identified. RNAi works well in cultured fly and human cells, and several methods have been developed that permit limited use *in vivo*. This approach readily lends itself to automation. When used in conjunction with the known sequences of all genes in both the model organism and humans, RNAi is likely to have a major role in the evolving field of "functional genomics," the high-throughput analysis of every gene product encoded by the genome. Indeed, in a technical tour de force, in two recent studies RNAi was used to examine the consequences of inactivation of 86 percent of the known genes in the worm.^{43,44} In one of these investigations the worms were examined for changes in fat storage. Human orthologues of these genes may help to determine susceptibility to obesity or diabetes.

TOWARD THERAPEUTICS

In general, the development of useful therapeutic agents lags behind the understanding of the mech-

anisms of disease. There are currently no drugs in regular use that were developed as a result of studies in simple model organisms, but two studies have led to the identification of possible therapeutic agents. In the first study, the use of cyclopamine was found to be beneficial in the treatment of basal-cell carcinoma.⁴⁵ Cyclopamine, a compound in the corn lily, *Veratrum californicum*, causes fetal prosencephaly in sheep. There is a similar abnormality in mice and humans lacking a *hedgehog* gene, which encodes a signaling molecule essential for early tissue differentiation.⁴⁶ Genetic screening in the fly first clarified the signaling pathway whereby the *hedgehog* gene interacts with the transmembrane protein Patched and its partner Smoothed to initiate a signaling cascade that regulates cellular differentiation. Cyclopamine was found to inhibit Smoothed, thereby suppressing *hedgehog* signaling,^{47,48} whereas Patched is now known to be the target of mutations in Gorlin's syndrome and basal-cell carcinoma, both diseases associated with increased *hedgehog* signaling. Together, these observations raise the possibility that topical cyclopamine could be used in the treatment of locally advanced skin cancers.

Another discovery concerns the possible use of sirolimus (rapamycin), an antibiotic with immunosuppressive properties, in the treatment of the congenital abnormality tuberous sclerosis. Rapamycin antagonizes the function of the TOR (target of rapamycin) kinase, a signaling molecule activated by several growth-promoting stimuli.⁴⁹ Studies in the fly indicated that the tuberous sclerosis genes *TSC1* and *TSC2* restrict cell growth and that they function in cellular pathways known to impinge on TOR activation.⁵⁰⁻⁵² The finding that in tuberous sclerosis mutations in *TSC1* and *TSC2* cause excessive TOR kinase activity⁵³ provides a rationale for exploring the possible use of rapamycin in severe cases of tuberous sclerosis.

Beyond these fortuitous examples lies the prospect of large-scale screening of drugs based on phenotypes defined in model organisms. Traditional screening for new drugs that modulate cellular pathways requires the use of large libraries of compounds to test for inhibition of enzymatic activity, *in vitro* binding to a purified protein, or more complex mammalian-cell-based assays. By contrast, abnormal signaling in the eye of the fly, aberrant apoptosis in the worm, or developmental defects in zebrafish might make possible novel approaches to the discovery of drugs that correct the malfunction





Figure 3. Modifier Screening in *Drosophila melanogaster*.

The elaborate structure of the compound eye of the fly is unnecessary for its feeding and breeding in the laboratory environment, but it makes possible the detection of abnormalities in the multiple cellular pathways required for cellular proliferation and differentiation. Expression of an abnormal *Ras* gene in fly retinal cells leads to an abnormal appearance of the fly's eye, a so-called rough-eye phenotype. Inducing random mutations in other genes (e.g., with the use of irradiation) may cause additional mutations in genes that function in the same pathway as *Ras*. Genes that undergo a mutation that causes a worsening of the phenotype are called enhancers, whereas genes that cause a correction of the phenotype are called suppressors. Genetic mapping is used to identify both these types of genes and to study how they interact with the *Ras* gene.



of a specific cellular pathway in the context of a whole organism.

THE FUTURE

The complete annotation of the human genome and the sequencing of the genomes of an increasing number of model organisms will together provide an unparalleled opportunity to use comparative genomics to study gene function. There remains much to learn from the study of the conservation, divergence, and convergence of genes and their pathways during evolution, and with the use of model organisms, these advances can make important contributions to medical research. Early studies of the fruit fly yielded many pillars of human genetics, among them the chromosomal theory of inheritance and the mutagenic effects of x-rays. Along with a menagerie of worms, zebrafish, and other small creatures, the fly has now entered a new stage of discovery, in which the modeling of specific cellular pathways implicated in human diseases may contribute to the search for new treatments.

Jacques Monod's reported observation, men-

tioned earlier, that discoveries about gene regulation point to a relation between *E. coli* and the elephant may now be expanded to include yeast, the worm, the zebrafish, and also — as the 18th-century poet William Blake foresaw — the fly:

Am not I
A fly like thee?
Or art not thou
A man like me?⁵⁴

From the Massachusetts General Hospital Cancer Center, Charlestown, Mass., and Harvard Medical School, Boston.

1. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. *Nature* 2001;409:860-921. [Errata, *Nature* 2001;411:720, 412:565.]
2. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. *Science* 2001;291:1304-51. [Erratum, *Science* 2001;292:1838.]
3. Hamosh A, Scott AF, Amberger J, Bocchini C, Valle D, McKusick VA. Online Mendelian Inheritance in Man (OMIM), a knowledge-base of human genes and genetic disorders. (Also available at <http://www.ncbi.nlm.nih.gov/omim>.) *Nucleic Acids Res* 2002;30:52-5.
4. Ptashne M, Johnson AD, Pabo CO. A genetic switch in a bacterial virus. *Sci Am* 1982;247:128-30, 132, 134-40.
5. Goffeau A, Barrell BG, Bussey H, et al. Life with 6000 genes. *Science* 1996;274:546, 563-7.
6. The *C. elegans* Sequencing Consortium. Genome sequence of

- the nematode *C. elegans*: a platform for investigating biology. *Science* 1998;282:2012-8. [Errata, *Science* 1999;283:35, 2103, 285:1493.]
7. Adams MD, Celniker SE, Holt RA, et al. The genome sequence of *Drosophila melanogaster*. *Science* 2000;287:2185-95.
 8. Forsburg SL. The art and design of genetic screens: yeast. *Nat Rev Genet* 2001;2:659-68.
 9. St Johnston D. The art and design of genetic screens: *Drosophila melanogaster*. *Nat Rev Genet* 2002;3:176-88.
 10. Jorgensen EM, Mango SE. The art and design of genetic screens: *Caenorhabditis elegans*. *Nat Rev Genet* 2002;3:356-69.
 11. Patton EE, Zon LI. The art and design of genetic screens: zebrafish. *Nat Rev Genet* 2001;2:956-66.
 12. Rubin GM, Yandell MD, Wortman JR, et al. Comparative genomics of the eukaryotes. *Science* 2000;287:2204-15.
 13. Reiter LT, Potocki L, Chien S, Gribkov M, Bier E. A systematic analysis of human disease-associated gene sequences in *Drosophila melanogaster*. *Genome Res* 2001;11:1114-25.
 14. Shin JT, Fishman MC. From zebrafish to human: modular medical models. *Annu Rev Genomics Hum Genet* 2002;3:311-40.
 15. Langenau DM, Traver D, Ferrando AA, et al. Myc-induced T cell leukemia in transgenic zebrafish. *Science* 2003;299:887-90.
 16. Hartwell LH, Culotti J, Reid B. Genetic control of the cell-division cycle in yeast. I. Detection of mutants. *Proc Natl Acad Sci U S A* 1970;66:352-9.
 17. Nurse P, Thuriaux P, Nasmyth K. Genetic control of the cell division cycle in the fission yeast *Schizosaccharomyces pombe*. *Mol Gen Genet* 1976;146:167-78.
 18. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. *Science* 1989;246:629-34.
 19. Nusslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in *Drosophila*. *Nature* 1980;287:795-801.
 20. Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode *C. elegans*. *Cell* 1986;44:817-29.
 21. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. *Cell* 1993;75:1027-38.
 22. Hahn H, Wicking C, Zaphropoulos PG, et al. Mutations of the human homolog of *Drosophila* patched in the nevoid basal cell carcinoma syndrome. *Cell* 1996;85:841-51.
 23. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. *Science* 1996;272:1668-71.
 24. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. *Nature* 2001;413:316-22.
 25. Moberg KH, Bell DW, Wahrer DC, Haber DA, Hariharan IK. Archipelago regulates cyclin E levels in *Drosophila* and is mutated in human cancer cell lines. *Nature* 2001;413:311-6.
 26. Koepf DM, Schaefer LK, Ye X, et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. *Science* 2001;294:173-7.
 27. Spruck CH, Strohmaier H, Sangfelt O, et al. hCDC4 Gene mutations in endometrial cancer. *Cancer Res* 2002;62:4535-9.
 28. Donovan A, Brownlie A, Zhou Y, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. *Nature* 2000;403:776-81.
 29. Montosi G, Donovan A, Totaro A, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. *J Clin Invest* 2001;108:619-23.
 30. Njajou OT, Vaessen N, Joosse M, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. *Nat Genet* 2001;28:213-4.
 31. Fortini ME, Bonini NM. Modeling human neurodegenerative diseases in *Drosophila*: on a wing and a prayer. *Trends Genet* 2000;16:161-7.
 32. Gusella JF, MacDonald ME. Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. *Nat Rev Neurosci* 2000;1:109-15.
 33. Warrick JM, Paulson HL, Gray-Board GL, et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in *Drosophila*. *Cell* 1998;93:939-49.
 34. Jackson GR, Salecker I, Dong X, et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of *Drosophila* photoreceptor neurons. *Neuron* 1998;21:633-42.
 35. Faber PW, Alter JR, MacDonald ME, Hart AC. Polyglutamine-mediated dysfunction and apoptotic death of a *Caenorhabditis elegans* sensory neuron. *Proc Natl Acad Sci U S A* 1999;96:179-84.
 36. Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, Bonini NM. Suppression of polyglutamine-mediated neurodegeneration in *Drosophila* by the molecular chaperone HSP70. *Nat Genet* 1999;23:425-8.
 37. Kazemi-Esfarjani P, Benzer S. Genetic suppression of polyglutamine toxicity in *Drosophila*. *Science* 2000;287:1837-40.
 38. Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, et al. Identification of genes that modify ataxin-1-induced neurodegeneration. *Nature* 2000;408:101-6.
 39. Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in *Drosophila*. *Nature* 2001;413:739-43.
 40. Feany MB, Bender WW. A *Drosophila* model of Parkinson's disease. *Nature* 2000;404:394-8.
 41. Francis R, McGrath G, Zhang J, et al. *aph-1* and *pen-2* are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. *Dev Cell* 2002;3:85-97.
 42. Hannon GJ. RNA interference. *Nature* 2002;418:244-51.
 43. Kamath RS, Fraser AG, Dong Y, et al. Systematic functional analysis of the *Caenorhabditis elegans* genome using RNAi. *Nature* 2003;421:231-7.
 44. Ashrafi K, Chang FY, Watts JL, et al. Genome-wide RNAi analysis of *Caenorhabditis elegans* fat regulatory genes. *Nature* 2003;421:268-72.
 45. Bale AE. Sheep, lilies and human genetics. *Nature* 2000;406:944-5.
 46. Verlinsky Y, Rechitsky S, Verlinsky O, et al. Preimplantation diagnosis for sonic hedgehog mutation causing familial holoprosencephaly. *N Engl J Med* 2003;348:1449-54.
 47. Taipale J, Chen JK, Cooper MK, et al. Effects of oncogenic mutations in Smoothed and Patched can be reversed by cyclopamine. *Nature* 2000;406:1005-9.
 48. Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothed. *Genes Dev* 2002;16:2743-8.
 49. Schmelzle T, Hall MN. TOR, a central controller of cell growth. *Cell* 2000;103:253-62.
 50. Tapon N, Ito N, Dickson BJ, Treisman JE, Hariharan IK. The *Drosophila* tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. *Cell* 2001;105:345-55.
 51. Potter CJ, Huang H, Xu T. *Drosophila* Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. *Cell* 2001;105:357-68.
 52. Gao X, Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. *Genes Dev* 2001;15:1383-92.
 53. Kwiatkowski DJ, Zhang H, Bandura JL, et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. *Hum Mol Genet* 2002;11:525-34.
 54. Blake W. *The fly*. In: Erdman DV, ed. *The complete poetry and prose of William Blake*. Rev. ed. Charlottesville: University of Virginia Institute for Advanced Technology in the Humanities, 1988.

Copyright © 2003 Massachusetts Medical Society.